Anika misses revenue, earnings estimates in Q3

Anika Therapeutics (NSDQ:ANIK) missed expectations on Wall Street with its third quarter results, the company reported yesterday after the market closed.

The Bedford, Mass.-based company posted profits of $14.6 million, or 47¢ per share, on sales of $27.2 million for the 3 months ended Sept. 30, for a bottom-line loss of -0.3% on sales growth of 5.4% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Anika misses revenue, earnings estimates in Q3 appeared first on MassDevice.

from MassDevice http://ift.tt/2yPmkUe